Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and safety of 9-valent HPV vaccine in HIV-positive women
2019-003486-17Phase 4Active
- Sponsor
- CARMEN HIDALGO TENORIO
- Start
- Jan 2020
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, cervical dysplasia (CIN), anal intraepithelial neoplasia (AIN) and 2 more, sponsored by CARMEN HIDALGO TENORIO. Primary endpoint: New infections and dysplasia incidence. Started Jan 2020; status: active.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectioncervical dysplasia (CIN)anal intraepithelial neoplasia (AIN)Cervical Cancer (CC)anal cancer
Beyond the preview
Go deeper on 2019-003486-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003486-17.